{"id":63189,"date":"2026-06-01T07:02:56","date_gmt":"2026-06-01T05:02:56","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/"},"modified":"2026-06-01T07:02:56","modified_gmt":"2026-06-01T05:02:56","slug":"genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/","title":{"rendered":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>Late-breaking Phase II data highlight enicepatide\u2019s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity<\/i><\/li>\n<li>\n<i>Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide\u2019s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity<\/i><\/li>\n<li>\n<i>A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option<\/i><\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif.&#8211;(BUSINESS WIRE)&#8211;Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that new data from its obesity portfolio will be presented at the 2026 Scientific Sessions of the American Diabetes Association<sup>\u00ae<\/sup> (ADA). The insights demonstrate significant progress in addressing a range of unmet needs for people living with obesity or overweight such as long-term treatment adherence, which could be supported by a favorable safety and tolerability profile.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/5\/GNE_Logo_Strapline_BLK_081525.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/5\/GNE_Logo_Strapline_BLK_081525.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/21\/GNE_Logo_Strapline_BLK_081525.jpg\"><\/a><\/p>\n<p>\n\u201cThe data we will present at ADA highlight the growing strength of our obesity portfolio, exemplified by the robust efficacy and distinct tolerability profiles of enicepatide and petrelintide,\u201d said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. \u201cThe clinical insights from these studies demonstrate how our portfolio may offer more tailored, individualized treatment options for people living with obesity.\u201d<\/p>\n<p>\nThe data presented on Genentech\u2019s obesity assets include:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nEnicepatide (CT-388): Late-breaking data from the Phase II (CT388-103) study will highlight clinical weight loss outcomes from investigational enicepatide in people living with overweight\/obesity. The dual GLP-1\/GIP receptor agonist is also being investigated in an additional Phase II study (CT388-104) to evaluate its efficacy, safety and tolerability in participants who are living with obesity or are overweight and have type 2 diabetes (T2D). These data suggest that enicepatide could emerge as an important medicine in its own right and also a key backbone for potential combination therapies from Genentech\u2019s cardiometabolic pipeline.<\/li>\n<li>\nPetrelintide: Late-breaking data from the Phase II ZUPREME-1 trial highlight the efficacy and safety of petrelintide, an investigational human amylin analog being evaluated for weight management in people living with overweight and obesity. The ongoing Phase II petrelintide monotherapy trial, ZUPREME-2 is evaluating petrelintide versus placebo in people living with obesity or overweight and T2D. As monotherapy and in combination with enicepatide, petrelintide can become an important component of Genentech&#8217;s portfolio.<\/li>\n<\/ul>\n<p>\nGenentech continues to advance its weight management pipeline rapidly, moving both enicepatide and petrelintide into Phase III development while initiating a Phase II multi-arm combination trial in mid-2026.<\/p>\n<p>\nGenentech is pleased to invite investors and analysts to participate in a <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.roche.com%2Finvestors%2Fupdates%2Finv-update-2026-05-07b&amp;esheet=54543921&amp;newsitemid=20260531568623&amp;lan=en-US&amp;anchor=virtual+event&amp;index=1&amp;md5=9bd78c5b87b761216e00bf2c8ec341c7\" rel=\"nofollow\" shape=\"rect\">virtual event <\/a>on Monday, June 8, 2026, that will highlight the new data from the Phase II CT388-103 study of enicepatide, as well as from the Phase II ZUPREME-1 study of petrelintide.<\/p>\n<p>\nAdditional details on presentations at the ADA\u2019s Scientific Sessions are included below and the full abstracts will be available in <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdiabetesjournals.org%2Fjournals%2Fpages%2Fscientific-sessions-abstracts&amp;esheet=54543921&amp;newsitemid=20260531568623&amp;lan=en-US&amp;anchor=Diabetes&amp;index=2&amp;md5=54f85d24fff3f3cd66ee09350c033a80\" rel=\"nofollow\" shape=\"rect\"><i>Diabetes<\/i><\/a><i>.<\/i><\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Asset<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Title \/ Lead author<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwtopsingle bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Abstract \/ Presentation details<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"2\">\n<p class=\"bwcellpmargin\">\nEnicepatide (CT-388)<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCT-388, a cAMP Signal-Biased GLP-1\/GIP Receptor Agonist, Achieves Clinically Meaningful Weight Loss in People With Overweight\/Obesity: A 48-Week Phase 2 Study.<\/p>\n<p class=\"bwcellpmargin\">\n<i>Lingvay I, et al.<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLate Breaking Poster Session (2813-LB)<\/p>\n<p class=\"bwcellpmargin\">\nSunday, June 7<\/p>\n<p class=\"bwcellpmargin\">\n12:30 pm &#8211; 1:30 pm CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>As above<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nE-Theater presentation Monday, June 8 12:30 pm CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwleftsingle bwrightsingle bwpadl0 bwwidth7\" colspan=\"1\" rowspan=\"4\">\n<p class=\"bwcellpmargin\">\nPetrelintide<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nAmylin as a Novel Diabetes and Obesity Therapy.<\/p>\n<p class=\"bwcellpmargin\">\n<i>Garvey T, et al.<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nScientific Symposium<\/p>\n<p class=\"bwcellpmargin\">\nFriday, June 5<\/p>\n<p class=\"bwcellpmargin\">\n3:45 pm &#8211; 5:15 pm CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPetrelintide, a human amylin analog for weight management: efficacy and safety from the Phase 2 trial, ZUPREME-1.<\/p>\n<p class=\"bwcellpmargin\">\n<i>Garvey T, et al.<\/i><\/p>\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLate Breaking Poster Session (3083-LB)<\/p>\n<p class=\"bwcellpmargin\">\nSunday, June 7<\/p>\n<p class=\"bwcellpmargin\">\n12:30 pm &#8211; 1:30 pm CT (ePoster: Saturday, June 6 1:30 pm &#8211; 1:40 pm CT)<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPetrelintide elicits distinct effects on eating pattern and maintains locomotor activity compared to semaglutide in rats with diet-induced obesity.<\/p>\n<p class=\"bwcellpmargin\">\n<i>Gradel A, et al.<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster Presentation<br \/>\n<br \/>Monday, June 8<\/p>\n<p class=\"bwcellpmargin\">\n12:30 pm &#8211; 1:30 pm CT<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth55\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nLong-acting amylin analog petrelintide does not delay gastric emptying.<\/p>\n<p class=\"bwcellpmargin\">\n<i>Griffin J, et al.<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl0 bwwidth38\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nPoster Presentation<br \/>\n<br \/>Monday, June 8<\/p>\n<p class=\"bwcellpmargin\">\n12:30 pm &#8211; 1:30 pm CT<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>About Enicepatide (CT-388)<\/b><\/p>\n<p>\nEnicepatide is an investigational once-weekly subcutaneous injectable, dual GLP-1\/GIP receptor agonist being developed for the treatment of people living with obesity and associated comorbidities including type 2 diabetes (T2D). Enicepatide was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no beta-arrestin recruitment on either receptor. This biased signalling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity.<\/p>\n<p>\n<b>About Petrelintide<\/b><\/p>\n<p>\nPetrelintide is an investigational long-acting amylin analog suitable for once-weekly subcutaneous administration that has been designed with chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation and co-administration with other peptides.<sup>1<\/sup> Amylin is produced in the pancreatic beta cells and co-secreted with insulin in response to ingested nutrients. Amylin receptor activation has been shown to reduce body weight by restoring sensitivity to the satiety hormone leptin <sup>2,3<\/sup> inducing a sense of feeling full faster.<\/p>\n<p>\n<b>About Obesity <\/b><\/p>\n<p>\nObesity is recognized as the greatest single risk factor for chronic disease globally. The condition is associated with many health challenges and more than 200 comorbidities, including type 2 diabetes, cardiovascular diseases, fatty liver, and chronic kidney disease. By 2035, over four billion people (more than half of the global population) are projected to be living with excess weight or obesity, a trend affecting nearly every country. This rise is driven by a complex mix of genetics and biology as well as behavioral, environmental and socioeconomic factors, placing an increased strain on healthcare systems due to the associated burden of comorbidities and reduced quality of life.<\/p>\n<p>\n<b>About Genentech<\/b><\/p>\n<p>\nFounded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.gene.com%2F&amp;esheet=54543921&amp;newsitemid=20260531568623&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.gene.com&amp;index=3&amp;md5=45578088ed206842310b81025b82ce56\" rel=\"nofollow\" shape=\"rect\">http:\/\/www.gene.com<\/a>.<\/p>\n<p>\n<b>References<\/b><\/p>\n<p>\n<sup>1<\/sup> Eriksson et al. Presentation at ObesityWeek, November 1\u20134, 2022, San Diego, CA. Link: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.zealandpharma.com%2Fmedia%2F0gnfxg4b%2Fzp8396-sema-coformulation-obesityweek-2022.pdf&amp;esheet=54543921&amp;newsitemid=20260531568623&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.zealandpharma.com%2Fmedia%2F0gnfxg4b%2Fzp8396-sema-coformulation-obesityweek-2022.pdf&amp;index=4&amp;md5=b632d63f81cdbc073765f1149cb6e26c\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.zealandpharma.com\/media\/0gnfxg4b\/zp8396-sema-coformulation-obesityweek-2022.pdf<\/a>.<br \/>\n<br \/><sup>2<\/sup> Mathiesen et al. Eur J Endocrinol 2022;186(6):R93\u2013R111<br \/>\n<br \/><sup>3<\/sup> Roth et al. Proc Natl Acad Sci U S A 2008;105(20):7257\u20137262<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nMedia Contact: Meghan Hindman (650) 467-6800<br \/>\n<br \/>Advocacy Contact: Danielle Haney (240) 805-4810<br \/>\n<br \/>Investor Contacts: Loren Kalm (650) 225-3217<br \/>\n<br \/>Bruno Eschli +41 61 687 5284<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Late-breaking Phase II data highlight enicepatide\u2019s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide\u2019s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-63189","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Late-breaking Phase II data highlight enicepatide\u2019s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide\u2019s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T05:02:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions\",\"datePublished\":\"2026-06-01T05:02:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/\"},\"wordCount\":1053,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260531568623\\\/en\\\/2738585\\\/22\\\/GNE_Logo_Strapline_BLK_081525.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/\",\"name\":\"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260531568623\\\/en\\\/2738585\\\/22\\\/GNE_Logo_Strapline_BLK_081525.jpg\",\"datePublished\":\"2026-06-01T05:02:56+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260531568623\\\/en\\\/2738585\\\/22\\\/GNE_Logo_Strapline_BLK_081525.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260531568623\\\/en\\\/2738585\\\/22\\\/GNE_Logo_Strapline_BLK_081525.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/","og_locale":"en_US","og_type":"article","og_title":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend","og_description":"Late-breaking Phase II data highlight enicepatide\u2019s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide\u2019s efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/","og_site_name":"Pharma Trend","article_published_time":"2026-06-01T05:02:56+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions","datePublished":"2026-06-01T05:02:56+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/"},"wordCount":1053,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/","url":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/","name":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg","datePublished":"2026-06-01T05:02:56+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260531568623\/en\/2738585\/22\/GNE_Logo_Strapline_BLK_081525.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/genentech-to-present-new-data-advancing-its-obesity-portfolio-at-the-american-diabetes-associations-2026-scientific-sessions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Genentech to Present New Data Advancing Its Obesity Portfolio at the American Diabetes Association\u2019s 2026 Scientific Sessions"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63189","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63189"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63189\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63189"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63189"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63189"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}